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PRedefining Normal Low-Density Lipoprotein Cholesterol
A Strategy to Unseat Coronary Disease as the Nation’s Leading Killer
James S. Forrester, MD
Los Angeles, California
The new Adult Treatment Panel guidelines will be published in 2011. This paper suggests the consideration of
major changes in the existing management guidelines for low-density lipoprotein cholesterol management
based on 2 fundamental principles: return the low-density lipoprotein cholesterol level to the normal range and
begin treatment closer to disease onset. These principles suggest the value of rethinking all 3 of the principal
features of the Adult Treatment Panel III guidelines for low-density lipoprotein cholesterol management: the initi-
ation criteria, the use of variable targets, and the level of the treatment target. Because the principal issue sur-
rounding guideline change is likely to be uncertainty concerning cost and toxicity, the text of new guidelines
would have to completely satisfy this concern by strong emphasis on a prudent conservative approach to imple-
mentation and would include both cautionary data and caveats concerning the tradeoffs between the potency,
cost, and toxicity of statins. The proposed changes in the guidelines, if combined with effective implementation,
would likely lead to the displacement of atherosclerotic disease as the nation’s number 1 killer. This review pro-
vides a logical rationale and discusses the pros and cons for each of the proposed changes. (J Am Coll Cardiol
2010;56:630–6) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.090a
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Aometime in 2011, a group of experts in lipidology will
nalize a set of recommendations that will alter the preven-
ive management of coronary heart disease for the next
ecade. These new Adult Treatment Panel (ATP) guide-
ines will be among the most important in all of medicine
or 2 reasons. They will deal with the leading cause of
orbidity and mortality in the Western world. They will be
ndorsed by the U.S. Food and Drug Administration, and
illions of health care practitioners worldwide will imple-
ent the recommendations. Ironically, any proposed
hange to the guidelines cannot be free of controversy
ecause these particular guidelines, unlike many in cardiol-
gy, cannot be based on rigorous medical science. Instead,
ike the existing ATP III guidelines, they will have to find
he practical middle ground between scientific proof and
ogical inference. This review proposes a logical rationale for 3
ajor changes in the existing management guidelines for
ow-density lipoprotein cholesterol (LDL-C) that, combined
ith effective implementation, would lead to displacement of
therosclerotic disease as the nation’s number 1 killer.
If the new recommendations are to dislodge coronary
therosclerotic disease as the leading cause of death, we
ight begin with the logical question: Is there an LDL-C
evel at which recurrent coronary events are effectively
rom The Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Cardiology,
os Angeles, California. Dr. Forrester has received Speakers’ Bureau honoraria in the
ast 2 years from Merck, Pfizer, AstraZeneca, Bristol-Myers Squibb, Berkeley Heart
ab, Sanofi-Aventis, and St. Jude Medical.O
Manuscript received November 3, 2009; revised manuscript received November 25,
009; accepted November 30, 2009.rrested and/or new atheroma do not develop? Although it
s tempting to term this the normal level of LDL-C, we
annot say that it would be devoid of long-term adverse
utcomes, so a more precise and descriptive term may be the
utative normal LDL-C level.
he Asymptomatic Population
s a Putative Normal
he earliest approach to defining a normal level of LDL-C
as traditional: determine its Gaussian distribution in a
linically asymptomatic population. At that time, the cal-
ulated median LDL-C level was approximately 130 mg/dl
1). In the existing ATP III guidelines, this value appears as
oth the level for initiating therapy in patients with disease
nd as a therapeutic target for those without known disease.
n population studies, however, 35% of patients with myo-
ardial infarction are asymptomatic before the event, so a
ormal population cannot be defined by the absence of
ymptoms. Further, in statin trials, only 25% to 35% of
vents are prevented as LDL-C is reduced to 100 to 130
g/dl, independent of the presence or absence of symp-
oms. We may infer that clinical presentation cannot be
sed to establish a putative normal LDL-C level and that
he 130 mg/dl cut point has little support in the recent
ublished literature.
efining Putative Normal From
onatherosclerotic Populations
n alternative approach was suggested 5 years ago by
’Keefe et al. (2). Beginning with the total cholesterol level
o
s
m
L
w
n
O
v
l
r
r
n
d
s
s
L
m
T
o
T
s
i
t
U
m
6
(
P
s
m
r
1
L
t
i
t
b
t
s
f
m
m
c
o
n
c
m
I
N
A
a
L
t
t
a
i
(
t
T
l
o
t
a
r
a
t
F
b
t
k
t
(
o
c
i
s
c
d
c
d
c
p
631JACC Vol. 56, No. 8, 2010 Forrester
August 17, 2010:630–6 Redefining Normal LDLf 80 to 110 mg/dl in nonatherosclerotic wild mammalian
pecies, they calculated the LDL-C level to be approxi-
ately 35 to 70 mg/dl (Fig. 1). Humans are born with
DL-C levels in this range, but the level gradually increases
ith age. At least 2 adult human populations, however, do
ot exhibit this progressive increase in LDL-C with age.
ne population consists of hunter-gatherer societies, di-
erse in geographic location and ethnic origin but arguably
iving the way humans did 10,000 years ago. LDL-C levels
emain in the 35 to 70 mg/dl range. In modern societies,
ural Chinese blood levels often fall within this range. In
eonates and these 2 adult groups, atherosclerotic coronary
isease is rare. The consistency of these diverse human data
ources, taken together with the mammalian species data,
upports the speculation that the putative normal range of
DL-C in adult humans may be approximately 35 to 70
g/dl.
esting a Putative Normal Range
f LDL-C in Humans
wo recent randomized clinical trials allow the next logical
tep: examining the effect of therapeutic LDL-C lowering
nto this putative normal range. In ASTEROID (A Study
o Evaluate the Effect of Rosuvastatin on Intravascular
ltrasound), reduction of LDL-C from 130 mg/dl to 61
g/dl (12% 40 mg/dl LDL-C and 41% between 40 and
0 mg/dl) resulted in regression of carotid atherosclerosis
3). In JUPITER (Justification for the Use of Statins in
rimary Prevention: an Intervention Trial Evaluating Ro-
uvastatin), reduction of LDL-C from 108 mg/dl to 55
g/dl in an asymptomatic intermediate-risk population
esulted in a 44% reduction in adverse cardiac events to
Figure 1 The Level of LDL-C in
Different Species and Populations
The level of calculated low-density lipoprotein cholesterol (LDL-C) levels in wild
animals (baboon, monkey, horse, bear, rhinoceros, elephant, wild pig), neona-
tal humans, and hunter-gatherer societies is in the range of 35 to 70 mg/dl
(2). The mean LDL-C level in U.S. adults is approximately twice this value.
Because humans are the only animal species in this range (excluding some
animals domesticated for human consumption), a reasonable question is
whether the putative normal LDL-C for all mammals is in the 35 to 70 mg/dl
range.d.4% in those with on-treatment
DL-C 70 mg/dl (4). Neither
rial identified increased statin-
nduced toxicity at lower on-
reatment LDL-C levels.
These new data are supported
y linear extrapolation of on-
reatment LDL-C levels in both
econdary angiographic and primary prevention trials. In the
ormer, lesion progression reaches zero at an LDL-C of 67
g/dl and coronary events reach zero at approximately 30
g/dl (2). In primary prevention trials, major adverse
ardiac events reach zero at an on-treatment LDL-C level
f 57 mg/dl. Thus, to the lipid profiles in mammals,
eonatal humans, and isolated human societies, we may add
linical trials that suggest the putative normal LDL-C level
ay be approximately 35 to 70 mg/dl.
nsights Derived From
ew Lifetime Follow-Up Data
s LDL-C levels rise above the putative normal range,
therosclerosis begins to appear. At ages 12 to 17 years,
DL-C reaches 87 mg/dl, with approximately 5% to 7% of
his group already at a level 130 mg/dl (5). The mono-
onic progression of coronary atherosclerosis with decades of
ge has been documented by intracoronary ultrasound
maging of donor hearts at the time of transplantation (6)
Fig. 2). Plaques of at least 0.5 mm were found in 17% of 13
o 19 year olds and increased to 60% in 30 to 39 year olds.
he presence of these ultrasound-identified plaques predicts
ong-term morbidity and mortality at follow-up (7).
Of critical importance to the new guidelines, those at risk
f developing atherosclerosis can be identified in youth. In
he Bogalusa Heart Study, autopsy of young adults who had
previous risk factor analysis show those with3 childhood
isk factors had a 9-fold increase in atherosclerotic plaque
rea compared with those with none (8). Lipid abnormali-
ies in childhood also predict early onset of clinical disease.
or instance, in adults with onset of cardiovascular disease
etween ages 39 and 45 years, their childhood mean
riglyceride level of 127 mg/dl and body mass index of 24
g/m2 contrasted to those without clinical disease with a
riglyceride level of 72 mg/dl and a body mass index of 20
9). Finally, LDL-C lowering during early atheroma devel-
pment induces regression. In children with familial hyper-
holesterolemia, pravastatin 20 to 40 mg/day for 2 years
nduced a 24% reduction in LDL-C, accompanied by a
ignificant reduction in carotid intima-media thickness
ompared with both baseline and placebo controls, with no
ifference in growth, muscle, or liver enzymes or in endo-
rine function (10). We may conclude that atherosclerotic
isease begins in youth, that the risk of the development of
linical disease can be identified decades before its clinical
resentation, and that the disease can be arrested or reversed
Abbreviations
and Acronyms
ATP  Adult Treatment
Panel
LDL-C  low-density
lipoprotein cholesteroluring this period.
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Redefining Normal LDL August 17, 2010:630–6mplications for
ecommendations and Guidelines
n guideline jargon, the level of evidence of the putative
ormal LDL-C level is clearly C, supported only by
nference from existing data, as are the current guidelines. A
urther daunting issue is that if atherosclerotic disease
egins in youth, then the duration of disease vastly exceeds
he duration of randomized trials of lipid-lowering therapy
sed to support guideline development. From first princi-
les, a 2- to 5-year trial cannot be assumed to predict either
fficacy or toxicity over 40 to 60 years of therapy with
cientific rigor. The remarkable implication is that, unlike
ther guidelines, those for LDL-C now and for the fore-
eeable future will be based on inference (Table 1). At a
inimum, however, guidelines need basic principles that
erve as their foundation. The putative normal range of
DL-C and the appearance of disease as blood levels exceed
his range suggest 2 fundamental principles: return the
DI-C level to the normal range and begin treatment closer
o disease onset. The role of guidelines is then to translate
hese principles in a manner that maximizes the relationship
etween efficacy and risk at reasonable cost. In this context,
he putative normal LDL-C level, the origin of atheroscle-
osis in youth, and the availability of low-cost potent statins
uggest the value of rethinking all 3 of the principal features
Figure 2 Coronary Atherosclerosis in Young Adults
Intravascular ultrasound imaging in 262 heart transplant recipients at 2,014 sites
0.5 mm were defined as atherosclerotic. In this population, 52% had lesions, ra
years of age. In those with lesions, intima thickness averaged 1.1 mm and area s
establish the fact that coronary atherosclerosis begins in youth. If many of these i
tistic, therapeutic lowering of the LDC-C to the putative normal range might logical
fied. Images are reproduced with permission and figure is adapted from Tuzcu et af ATP III guidelines for LDL-C management: the initi- Ltion criteria, the use of variable targets, and the level of the
reatment target.
ethinking Initiation Criteria
he ATP III initiation levels incorporate 2 fundamental
roblems. First, they now seem far too high (e.g., 190 mg/dl
or Framingham low-risk individuals and 130 to 160 mg/dl
or asymptomatic individuals with risk factors). As 1 exam-
le, in the asymptomatic JUPITER population with a mean
DL-C level of 108 mg/dl, approximately one-half of the
1,477 segments in 574 coronary arteries. Lesions with an intima thickness
from 17% in individuals younger than 20 years to 85% in those older than 50
s was 33%. Data taken from a large number of age-stratified autopsy studies
als are those destined to become those who compose the 50% mortality sta-
n during this point in pathogenesis, provided that they can be accurately identi-
roof Versus Inference: Why Coronarytery Disease Requir s a Different MindsetTable 1 Proof Ve sus Infer nce: Why CoronaryArtery Disease Requires a Different Mindset
● Humans are the only free-living animal in which atherosclerosis develops,
so animal research cannot define natural history.
● The traditional use of apparently normal individuals to establish a normal range
cannot be used for LDL-C.
● The duration of the disease vastly exceeds the duration of randomized clinical
trials.
● The efficacy results of 2- to 5-year randomized trials cannot predict the efficacy
of 40 to 60 years of therapy.
● Acute toxicity results of trials are made grossly misleading by the 1-month
run-in period before randomization.
● Short-term absence of toxicity cannot be taken to predict long-term absence of
toxicity.
● As a consequence, guidelines for LDL-C management must be based on logical
inference rather than scientific rigor.within
nging
tenosi
ndividu
ly begi
l. (6).DL-C  low-density lipoprotein cholesterol.
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August 17, 2010:630–6 Redefining Normal LDLatients had a calculated 10-year risk Framingham risk level
10% (4). Nonetheless, there was a 44% reduction in events
hen LDL-C was reduced to the middle of the putative
ormal range. Second, an even more serious problem
nvolves calculating risk based on the 10-year probability of
cardiac event. The risk calculation is very heavily weighted
y age, such that the calculated mean 10-year risk for
5-year-old men increases 7-fold over 30 years (Fig. 3) (11).
ounger individuals with a high risk factor burden clearly
ave a high probability of atherosclerotic disease, but have a
ow calculated 10-year risk and thus do not become candi-
ates for treatment until the disease is very well established.
or asymptomatic individuals, the magnitude of the limi-
ation inherent in use of the 10-year risk rather than disease
athogenesis as the initiation criterion is substantial: ap-
roximately one-half of those in whom coronary artery
isease develops first present with either sudden death or
cute infarction.
Reorienting the initiation criteria toward the pathogen-
sis of atherosclerosis rather than its first clinical manifes-
ation is actually eminently feasible. Data to support at least
methods are currently available. An individual’s risk can be
xpressed relative to the average risk for that person’s age.
lternatively, the individual’s calculated risk can be ex-
ressed relative to optimal values. Finally, a third approach
ith the same philosophy is to calculate the Framingham
isk over 30 years rather than the current 10-year period
11). Each of these methods is amenable to creation of
imple objective initiation criteria. As an example, a young
Figure 3 Risk Factors and Coronary Atherosclerosis in Youth
The critical flaw in the use of the 10-year risk of a coronary event as an initia-
tion criterion. An example of the approximate 10- and 30-year Framingham risk
of coronary heart disease for a 25-year-old man with or without clinical risk fac-
tors (total cholesterol 150 mg/dl vs. 260 mg/dl; high-density lipoprotein cho-
lesterol 35 mg/dl vs. 60 mg/dl; systolic blood pressure 110 mm Hg vs. 160
mm Hg), smoking, and diabetes. A young man with 4 risk factors is at low
10-year risk (5%) whereas his risk of a cardiac event before age 55 years
exceeds 40%, and his risk is 5-fold greater than a man with no risk factors.
The arbitrary choice of 10-year risk of a coronary event needs to be replaced
with a method reflecting the pathogenesis of coronary artery disease, which
begins in young adults. This concept is incorporated in both the absolute
30-year risk and in the individual’s relative risk within his/her age group.sndividual with risk in the upper 10% of that age group, or
calculated 2- to 3-fold greater risk than optimum, or a
0% 30-year risk might be identified as a candidate for
harmacologic therapy. Independent of which methodology
s chosen, to dislodge atherosclerotic disease from its num-
er 1 position, it seems essential that the new guidelines
ncorporate the logical concept that a long-term disease
equires a long-term solution (i.e., that management begin
arlier in the course of the disease).
ethinking the LDL-C Target
logical LDL-C target for individuals selected for therapy
s the putative normal range, with the proviso that it can be
chieved at acceptable cost in the absence of toxicity and
hat neither patient nor health care provider use drug
herapy as a substitute for lifestyle modification. Indeed, a
aturally or lifestyle-induced low LDL-C is not necessarily
he same as medication-induced low LDL-C. The alleged
fficacy of LDL-C lowering is derived predominantly from
-year clinical trials, whereas the magnitude of benefit
erived from an earlier and sustained lifetime of lower
DL-C is poorly defined. An experiment of nature provides
otential insight. In the ARIC (Atherosclerosis Risk in
ommunities) study of a free-living population, approxi-
ately 3% have sequence variants in the gene colloquially
alled PCSK-9 (pro-protein convertase subtilisin/kexin type
serine protease). These variants lower LDL-C by a mean
f approximately 19% compared with the general popula-
ion. Individuals with the PCSK mutation have had a mean
2% lower rate of cardiac events over the first 15 years of
bservation (Fig. 4) (12). These data suggest that the
fficacy of a lifetime of lower LDL-C level and the inference
hat if therapeutic lowering of LDL-C had a similar
ong-term impact in higher risk asymptomatic younger
ndividuals, well-constructed guidelines could result in a
ajor reduction in cardiac events. Thus, pathologic, epide-
iologic, and clinical trial data suggest that a single putative
ormal LDL-C target might reasonably replace existing
rbitrary multiple targets stratified by risk. The 70-mg/dl
arget for individuals with coronary artery disease and
iabetes is widely accepted as highly beneficial; simply
ffering this benefit to all individuals selected for treatment
eems reasonable, both because asymptomatic individuals
ay have life-threatening disease and because the patho-
enesis of the disease is identical.
ontrolling the Potential
ajor Expansion in Statin Use
n inevitable outcome of change in the LDL-C initiation
nd target would be a significant increase in the use of statin
rugs. The emergence of pharmacogenetic testing offers a
ossible solution to overuse. Although one reason for the
ailure of potent lipid-lowering therapy to markedly reduce
ardiac events is the “too little/too late” hypothesis; a secondAdapted, with permission, from Pencina et al. (11).
eldom considered reason is that the drugs are ineffective in
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Redefining Normal LDL August 17, 2010:630–6s yet unrecognized subsets. Pharmacogenetics suggests that
his is highly likely. For instance, one common polymor-
hism colloquially called KIF-6 (the kinesin-like protein 6
rg 719 Arg polymorphism) is thought to influence both
ntracellular transport and endothelial function. In carriers
f KIF-6, intensive statin therapy was associated with a
.8-fold greater reduction in cardiac events than in noncar-
iers in the PROVE IT (Pravastatin or Atorvastatin Eval-
ation and Infection Therapy) trial, despite the same level of
n-treatment LDL-C and CRP (13) (Fig. 5). Conversely,
oncarriers of the KIF-6 variant, approximately 40% of the
.S. population, experienced virtually no difference in
dverse outcomes despite the major differences in on-
Figure 4 The Effect of a Lifetime of LDL Lowering
The potential impact of a lifetime of lowered LDL-C. In the ARIC (Atherosclero-
sis Risk in Communities) study, 3% had a PCSK mutation at 15-year follow-up.
In the ARIC study, 3% or 12,787 subjects had DNA sequence variants in the
proprotein convertase subtilisin/kexin type 9 serine protease gene (PCSK9)
that are associated with reduced plasma levels of low-density lipoprotein (LDL)
(12). In the 3,363 black subjects, mutations were associated with a 28%
reduction in mean LDL cholesterol and an 88% reduction in the risk of coronary
heart disease. In the 9,524 white subjects, a sequence variation in PCSK9
was associated with a 15% reduction in LDL cholesterol and a 47% reduction
in risk. These data suggest that an early and long duration (lifetime) reduction
in LDL cholesterol lead to a substantial reduction in coronary events.
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Figure 5 Potential Value of Pharmacogenetics in Patient Selec
In the PROVE IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) trial
high-dose atorvastatin than with standard-dose pravastatin (left). In noncarriers, th
to treat with atorvastatin versus pravastatin to prevent 1 event was 10 in KIF6 carreatment LDL-C levels between the atorvastatin 80-mg
nd pravastatin 40-mg treatment groups. Thus, the dose
nd/or use of statins coincident with altered initiation and
arget criteria could be tempered by better selection of
herapeutic candidates if pharmacogenetic testing can pro-
ide insight into those most likely to benefit from therapy
Table 2).
rguing the Case for and Against
ethinking the Approach to LDL-C Management
here are strong arguments for avoiding these significant
hanges in the current guidelines (Table 3). The stepwise
pproach to LDL-C initiation levels and targets is a
ell-established structure. Guidelines typically are based on
andomized clinical trials, whereas the putative normal
ange of LDL-C is based on inference. For most, however,
heir principal concern will be uncertainties surrounding
oxicity and cost in implementation. Higher drug doses
mply an inevitable risk of increased drug toxicity. The risk
f long-term aggressive therapy beyond the 5-year clinical
rials is unknown, and, by their nature, long-delayed adverse
ffects are exceptionally difficult to detect. Even with potent
gents, a low LDL-C target clearly will not be achievable in
any individuals. Younger people may be reluctant to take
drug, creating practical hurdles to implementation. Be-
ause lowering initiation levels and targets increases the
umber of individuals on therapy, the number of individuals
ot benefiting from therapy must also increase. The impact
n health care cost is unpredictable.
Because the principal issue surrounding guideline change
s likely to be uncertainty concerning cost and toxicity, the
ext of new guidelines must completely satisfy this concern
y a strong emphasis on a prudent conservative approach to
mplementation presenting (as do the current guidelines)
he target as an desirable option rather than a mandate.
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August 17, 2010:630–6 Redefining Normal LDLurthermore, such a guideline would include both caution-
ry data and caveats concerning the tradeoffs among po-
ency, cost, and toxicity of statins, recognizing that these 2
ssues will probably outweigh achievement of the target in at
east one-fourth of treated patients. Specifically, randomized
rials typically report a 3% to 5% myalgia rate, grossly
isrepresenting clinical reality by using a run-in period
efore randomization, then not randomizing those in whom
ymptoms develop. A further safety consideration is that the
urrent optional 70-mg/dl target should probably have a
ower limit, even though there is little information to
upport any specific value. Because clinical trial data that
how no toxicity signal in the lower range are still largely
onfined to LDL-C levels above 50 mg/dl, a prudent lower
imit for LDL-C might be set at 50 mg/dl. Finally, the
uidelines would reasonably include a recommendation for
he creation of a post-publication database to allow more
igorous analysis of cost, toxicity, and effectiveness.
Given a cautious and conservative approach to each
ecommendation, the counterbalancing arguments for the
roposed changes are also strong (Table 3). A rough
stimate of the magnitude of event reduction in the broad
opulation coincident with treatment into the putative
ormal range can be made from randomized trials. In
UPITER, events in asymptomatic patients were reduced by
ust less than one-half; in the TNT (Treating to New
argets) trial, events were reduced by approximately one-
ourth as LDL-C was further reduced from approximately
00 mg/dl to just above the putative normal range. If
oughly similar outcomes were to follow implementation of
he proposed guideline changes, then the central argument
or change is that it would offer a realistic possibility of
islodging atherosclerotic disease as the leading cause of
orbidity and mortality. Although the new guidelines
annot be based on rigorous science, they can have a
onceptual foundation that the current guidelines lack.
uidelines represent the best judgment of a group of experts
t a point in time. They are not irreversible. Thus, new ATP
uidelines, like those with Level of Evidence: A, will have to
hanges in Current LDL-C Guidelines That Couldesult in a Major Reduction in Morbidity andortality t Acc ptable st
Table 2
Changes in urre t LDL-C Guidelines That Could
Result in a Major Reduction in Morbidity and
Mortality at Acceptable Cost
Criterion ATP III Guidelines Proposed
Initiation of treatment Based on events:
absolute 10-yr risk
Based on pathogenesis:
relative risk within the
individual’s age group
Use of a statin Those who meet risk
criteria
Further stratified by genetic
capability of response*
Choice of statin No recommendation Use a generic drug first in
asymptomatic individuals
Target of treatment Stratified by risk Putative normal LDL-C range
in all treated individuals,
in absence of toxicity
This proposal has a reasonable basis in recent published literature. Because it still requires further
alidation, it represents a concept, not a specific recommendation.
ATP  Adult Treatment Panel; LDL-C  low-density lipoprotein cholesterol.ncorporate medicine’s inherent uncertainties and will prob- Lbly require revision based on subsequent experience. Be-
ause guidelines classify data sources, however, no one need
e misled about the strength of supporting information. At
he practical level, potent generic statins allow the new
trategy to be implemented at low individual patient cost. A
etter distribution of individuals selected for statin therapy
robably can be achieved in the near future by the use of
harmacogenetics to predict the magnitude of response to
herapy. Finally, long-term preventive therapy for coronary
rtery disease has a well-established precedent. One may ask
hether a low-cost generic statin used in a well-defined
t-risk population might provide both more benefit and less
isk than aspirin.
LDL-C management recommendations will be devel-
ped in a new era in which longer term risk stratification,
ore objective initiation criteria, a reasonable LDL-C
arget, and pharmacogenetic stratification are clearly possi-
le. Because the concepts of a putative normal LDL-C and
nitiation criteria based on pathogenesis rather than first
linical event both incorporate uncertainties, it may be
orthwhile to recognize that small incremental change does
ot alter these uncertainties, but rather serves only to reduce
oth the risk of adverse outcomes and the potential benefit
f therapy. With the vision of dislodging atherosclerotic
isease as society’s leading cause of dollar expenditure,
orbidity, and mortality, a new conceptual foundation for
he LDL-C guidelines based on our current knowledge of
isease pathogenesis seems to merit very serious consider-
hanging the Approach to LDL-C Management:e Pros and ConsTable 3 Cha ging the Approach to LDL-C Management:The Pros and Cons
Favoring small incremental change in the current recommendations
Current approach uses a well-established and widely implemented structure.
Guideline changes based on inference are inherently controversial.
A lower LDL-C target will not be achievable in many individuals.
Young asymptomatic individuals may resist preventive therapy.
Expansion of the treated population may increase cost of care.
Use of higher drug doses will increase the incidence of drug toxicity.
The risk of long-term aggressive therapy beyond the 5 years is undefined.
Atherosclerosis is multifactorial, and risk varies widely at the same LDL-C
level.
Favoring more substantial change in the current recommendations
Atherosclerosis will likely remain the leading cause of morbidity/mortality with
only incremental changes.
Existing guidelines have little conceptual foundation and are viewed by many
as outdated.
New guidelines have the conceptual basis of returning LDL-C to normal and
initiating therapy earlier in the course of the disease.
Strength of information supporting change can be classified so no one is
misled.
Caveats regarding tradeoffs between drug potency, cost, and toxicity can be
included.
More aggressive strategy may be implemented at relatively low cost using
generic agents.
Pharmacogenetics may control cost by improving distribution of individuals
selected for therapy.
Current data suggest proposed changes in initiation and target LDL-C level will
result in a major reduction in morbidity and mortality.CL-C  low-density lipoprotein cholesterol.
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Redefining Normal LDL August 17, 2010:630–6tion for those facing the daunting task of creating guide-
ines in an uncertain world.
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